March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
HIV 102: How HIV Impacts the Immune System, CD4 Cells and Viral Load was the third in our eight-week webinar series that offers women living with HIV capacity building and training on HIV disease and treatment advocacy.
Learn what parents and providers need to know about HIV risk factors specific to teens and the importance of talking to your teen about HIV.